BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220222
DTEND;VALUE=DATE:20220225
DTSTAMP:20260516T003105
CREATED:20211101T103734Z
LAST-MODIFIED:20211101T103819Z
UID:31980-1645488000-1645747199@www.pharmajournalist.com
SUMMARY:3rd RAS/MAPK Pathway Targeted Drug Discovery Summit
DESCRIPTION:The Only Global RAS Dedicated Conference is Returning in 2022 with the 3rd RAS/MAPK Pathway Targeted Drug Discovery Summit!\nYear on year\, we are proud to unite the leading frontiers of the RAS industry to showcase expertise\, technical data and pipeline updates\, all geared toward accelerating the discovery and development of anti-RAS therapies. \nThis February 2022\, the summit returns to shine a spotlight onto pioneering discoveries and innovative strategies to target RAS\, including a focus on success in targeting mutations beyond G12C and efforts to shut down the RAS/MAPK pathway at every turn. \nAs the industry springboards off the significant success of G12C covalent inhibitors against KRAS mutant cancers\, leading experts are now shifting focus toward next-generation anti-RAS drugs\, considering how we can leverage the RAS signaling pathway to treat all RAS mutant cancers\, and overcome the critical escape mechanisms leading to treatment resistance. \nTo know more visit: https://ter.li/8ljo2k
URL:https://www.pharmajournalist.com/event/3rd-ras-mapk-pathway-targeted-drug-discovery-summit/
LOCATION:8:30am – 5pm | Boston\, MA In-Person and Digital Options Available
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220222
DTEND;VALUE=DATE:20220225
DTSTAMP:20260516T003105
CREATED:20211109T113013Z
LAST-MODIFIED:20211109T113013Z
UID:32042-1645488000-1645747199@www.pharmajournalist.com
SUMMARY:Next Generation CAR-TCR Summit
DESCRIPTION:As the CAR-T field continues to explode with new companies\, investment\, and clinical collaborations\, it’s more important than ever to stay ahead of the curve. Stakeholders across oncology are now turning to next generation developments and innovations to create the therapies of tomorrow. \nThat’s why CAR-TCR Europe has evolved into the Next Generation CAR-TCR Summit: your definitive platform focused on the 2.0\, next generation innovations in cell therapies. \nJoin you CAR-TCR community and network with 300+ innovators from large pharma\, biotech\, academia and regulatory boards at the only meeting dedicated to accelerating novel\, new generation cell therapies that are safer\, more effective and have meaningful impact in diseases beyond oncology. \nYou’ll hear insights into novel in-vivo delivery\, innovations in gene\, base & prime editing\, novel discovery platforms\, overcoming the hostile tumour microenvironment\, improving persistence & durability for greater clinical outcomes\, and more! \nKey insights will be shared from Matterhorn Biosciences\, Affini-T Therapeutics\, Kiromic BioPharma\, Antion Biosciences\, Zelluna Immunotherapy\, T-Kinfe Therapeutics\, AffyImmune and many more. Leverage their knowledge to deliver value to your entire cell therapy team. \nWith 3 in-depth streams exploring the hottest Novel Platforms\, Advanced Clinical Development of 3rd\, 4th and 5th generation cell therapies\, and the latest Manufacturing Innovations to revolutionise the production of large-scale cell therapy\, this is the ONLY meeting bringing you the next generation developments and innovations needed to create the therapies of tomorrow. \nWhether you are developing novel constructs\, new clinical trial strategies or innovative manufacturing approaches for large scale production\, this multi-tracked meeting can support your whole team and provide the tools needed to advance your own pipeline towards clinical and commercial success. \nView official event guide now for the full meeting details!
URL:https://www.pharmajournalist.com/event/next-generation-car-tcr-summit/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220222
DTEND;VALUE=DATE:20220225
DTSTAMP:20260516T003105
CREATED:20211129T180236Z
LAST-MODIFIED:20211129T180236Z
UID:32287-1645488000-1645747199@www.pharmajournalist.com
SUMMARY:2nd Mitochondria-Targeted Drug Development Summit
DESCRIPTION:We are happy to announce that the Mitochondria-Targeted Drug Development Summit\, focused on the pursuit for novel effective therapies for mitochondrial disorders/dysfunction\, will be delivered in-person\, for its 2nd edition.\nMitobridge/Astellas\, Minovia Therapeutics\, Abliva\, GenSight Biologics\, Stealth Biotherapeutics and many more will unite drive to better understand how to create effective and scalable mitochondrial therapies. \nTo know more visit: https://mitochondria-targets.com/
URL:https://www.pharmajournalist.com/event/2nd-mitochondria-targeted-drug-development-summit/
LOCATION:Hyatt Regency Boston / Cambridge\, 575 Memorial Dr\, Cambridge\, MA\, 02139\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR